Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Site News
Market: Market:

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) PR Newswire - PRF - Wed Sep 15, 6:30AM CDT

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - PRF - Wed Sep 8, 4:00PM CDT

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors Business Wire - Wed Aug 25, 6:00AM CDT

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors PR Newswire - PRF - Wed Aug 18, 6:30AM CDT

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

AIG : 55.95 (-1.89%)
BBIO : 50.10 (-0.67%)
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates Zacks - Thu Aug 5, 8:05AM CDT

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 29.03% and 7.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BBIO : 50.10 (-0.67%)
BridgeBio Pharma: Q2 Earnings Snapshot AP - Thu Aug 5, 6:57AM CDT

PALO ALTO, Calif. (AP) _ BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $96.3 million in its second quarter.

BBIO : 50.10 (-0.67%)
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update PR Newswire - PRF - Thu Aug 5, 6:30AM CDT

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - PRF - Wed Aug 4, 6:01PM CDT

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.10 (-0.67%)
BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations PR Newswire - PRF - Tue Jul 27, 6:30AM CDT

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - PRF - Mon Jul 12, 3:30PM CDT

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.10 (-0.67%)
Please wait...

Barchart Exclusives

Live Cattle: The Speedo Situation Barchart - Tue Sep 28, 10:50AM CDT
Some of the chatter I'm hearing about the live cattle market reminded me of a story. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot